Clinical trials: Estrogen
Breast Cancer
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist.
- Trial name
- NCT01823835
- Testing
- GDC-0810, LHRH Agonist, Palbociclib
- Where
- 14 sites in United States, Netherlands and 2 more
- Volunteers
- 152 people
- Sponsor
- Genentech, Inc.
Cardiovascular Diseases, Coronary Arteriosclerosis
Estrogen Replacement and Atherosclerosis (ERA) in Older Women
To determine if estrogen replacement therapy, with or without low dose progesterone, slows progression or induces regression of coronary atherosclerosis in postmenopausal women.
- Conditions
- Cardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease, Heart Diseases
- Trial name
- NCT00000549
- Testing
- estrogen replacement therapy, hormone replacement therapy, estrogens
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Type 1 Diabetes
Estrogen, Diabetes, and Endothelial Function
This study planned to learn more about women and how the drop in estradiol levels during menopause may affect their cardiovascular risk.
- Trial name
- EDEN (NCT04418908)
- Testing
- Cetrorelix acetate, 0.25 mg/day, Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Fertility
Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women
A single center, open label randomized clinical trial designed to examine ovarian follicular dynamics following attempted atresia induction during the late follicular and early luteal phase of the menstrual cycle using an…
- Trial name
- NCT01046578
- Testing
- Letrozole
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Contraception, Birth Control
International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
Multinational, comparative, prospective, active surveillance study that follows two cohorts. The primary objective of the study is to characterize and compare the risks of E4/Drospirenone (DRSP) with levonorgestrel-containing…
- Trial name
- INAS-NEES (NCT06028555)
- Where
- Germany
- Volunteers
- 101,000 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal
- Trial name
- NCT02152943
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Estrogen Receptor Positive HER2- Breast Cancer
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
The primary objectives of the Phase 1b Dose Escalation part of this study are to characterize the safety and tolerability of GS-5829 in combination with exemestane or fulvestrant and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT02983604
- Testing
- GS-5829, Exemestane, Fulvestrant
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Gilead Sciences
Breast Cancer
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level…
- Trial name
- NCT00651976
- Testing
- letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
- Where
- 5 sites in United States
- Volunteers
- 213 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Brown Seaweed as a Breast Cancer Preventive
Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the US.
- Trial name
- NCT01204957
- Testing
- Seaweed and Soy Protein
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00577122
- Testing
- Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Menopause
The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.
The purpose of this pilot study is to determine if suppressing estrogen in premenopausal women results in changes in gut microbiota and if dietary flaxseed modulates these changes.
- Trial name
- NCT03183102
- Testing
- Flaxseed
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897065
- Testing
- microarray analysis, polymerase chain reaction, protein expression analysis
- Where
- United States
- Volunteers
- 957 people
- Sponsor
- Massachusetts General Hospital
Insulin Resistance
Timing Estrogen After MenoPaUSe
The aim of the current study is to test whether the effect of estrogen on insulin metabolism depends on the timing of treatment relative to when a woman went through menopause.
- Trial name
- TEMPUS (NCT01605071)
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Breast Cancer
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.
- Trial name
- NCT01439711
- Testing
- letrozole, MRI, conventional surgery
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Obesity
Indole-3-Carbinol Effects on Estrogen Metabolism
This study will test a dietary supplement, indole-3-carbinol, for improving the estrogen profile in women across a range of body mass index.
- Trial name
- NCT00988845
- Testing
- Indole-3-carbinol
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Acromegaly
Estrogen Treatment in Acromegalic Women
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
- Trial name
- NCT00315107
- Testing
- Alesse
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Université de Montréal
Phthalate Exposure, Preeclampsia
The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia
Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes.
- Conditions
- Phthalate Exposure, Preeclampsia, Estrogen, Progestin
- Trial name
- NCT04777929
- Testing
- test Phthalates, estrogen and progesterone
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00253539
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Genitourinary Syndrome of Menopause (GSM)
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the…
- Trial name
- NCT07038070
- Testing
- Vaginal estrogen tablet, Via Solv Wellness (Hyaluronic Acid Therapy)
- Where
- United States
- Sponsor
- NYU Langone Health